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Serotonin reuptake inhibitors and cognitive-behavior therapy (CBT) are considered first-line treatments for obsessive-compulsive
disorder (OCD). However, little is known about their modulatory effects on regional brain morphology in OCD patients. We sought to
document structural brain abnormalities in treatment-naive OCD patients and to determine the effects of pharmacological and cognitive-
behavioral treatments on regional brain volumes. Treatment-naive patients with OCD (n¼ 38) underwent structural magnetic resonance
imaging scan before and after a 12-week randomized clinical trial with either fluoxetine or group CBT. Matched-healthy controls (n¼ 36)
were also scanned at baseline. Voxel-based morphometry was used to compare regional gray matter (GM) volumes of regions of
interest (ROIs) placed in the orbitofrontal, anterior cingulate and temporolimbic cortices, striatum, and thalamus. Treatment-naive OCD
patients presented smaller GM volume in the left putamen, bilateral medial orbitofrontal, and left anterior cingulate cortices than did
controls (po0.05, corrected for multiple comparisons). After treatment with either fluoxetine or CBT (n¼ 26), GM volume
abnormalities in the left putamen were no longer detectable relative to controls. ROI-based within-group comparisons revealed that GM
volume in the left putamen significantly increased (po0.012) in fluoxetine-treated patients (n¼ 13), whereas no significant GM volume
changes were observed in CBT-treated patients (n¼ 13). This study supports the involvement of orbitofronto/cingulo-striatal loops in
the pathophysiology of OCD and suggests that fluoxetine and CBT may have distinct neurobiological mechanisms of action.
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INTRODUCTION
Obsessive-compulsive disorder (OCD) is a chronic disorder
associated with clinically significant functional impairment
(Vikas et al, 2009). Available treatments with serotonin
reuptake inhibitors (SRIs) and cognitive-behavior therapy
(CBT) are effective for most patients, but impairing residual
symptoms and treatment non-response are common among
this population (Eddy et al, 2004). Therefore, understanding
brain-modulatory effects of these treatments is essential for
further improvement of therapeutic alternatives.
Numerous magnetic resonance imaging (MRI) studies of
OCD have demonstrated the presence of brain abnormal-
ities involving cortico-subcortical circuits that interconnect
the orbitofrontal cortex (OFC), anterior cingulate cortex
(ACC), striatum, and thalamus, as well as temporo-
limbic regions (Atmaca et al, 2008; Busatto et al, 2000;
Chamberlain et al, 2008; Harrison et al, 2009; Lacerda et al,
2003; Pujol et al, 2004; Radua and Mataix-Cols, 2009; Rauch
et al, 1994; Saxena and Rauch, 2000; Szeszko et al, 1999;
Valente et al, 2005; van den Heuvel et al, 2009). However,
it is unknown whether such abnormalities may be reversed
by specific treatments.
There are indications that SRIs modulate serotonin
neurotransmission earlier in certain subcortical regions
and later in the cerebral cortex (Blier and Bouchard, 1994;
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el Mansari et al, 1995). In the case of CBT, there is
increasing evidence implicating the medial prefrontal cortex
(medial OFC and rostral/subgenual subregions of the ACC)
in the mediation of its therapeutic action (Sotres-Bayon
et al, 2006; Milad et al, 2005). The medial prefrontal cortex
is a key regulatory region in the maintenance inhibition
of conditioned fear responses believed to underlie obses-
sive-compulsive symptoms and in the mediation of the
extinction process of such fear responses (Milad et al, 2005,
2007; Phelps et al, 2004; Sotres-Bayon et al, 2006). Thus,
although successful pharmacological interventions for
OCD seem to exert a preferential subcortical-cortical
‘bottom-up’ regulation in the brain, CBT seems to elicit
cortical-subcortical ‘top-down’ effects (Derryberry and
Tucker, 1992; Goldapple et al, 2004; Tucker et al, 1995).
Although there are a growing number of short-term
longitudinal functional neuroimaging studies documenting
regional brain activity changes in OCD patients after SRI
treatment or CBT (Baxter et al, 1992; Benkelfat et al, 1990;
Perani et al, 1995; Saxena et al, 2002, 2009; Schwartz et al,
1996; Swedo et al, 1992), longitudinal MRI studies investi-
gating treatment-related brain morphological changes are
still scarce. The few available longitudinal MRI studies in
this regard have been limited to the investigation of small
groups of children with short illness duration, treated in an
open, uncontrolled manner (Benazon et al, 2003; Gilbert
et al, 2000; Lazaro et al, 2009; Rosenberg et al, 2000; Szeszko
et al, 2004). Anecdotally, it has been suggested that SRIs
are more likely than CBT to modulate brain volumes in
OCD patients (Rosenberg et al, 2000). However, firmer
conclusions are limited because of the lack of longitudinal
MRI studies conducted in association with controlled,
randomized clinical trials investigating the brain structural
effects of these two modalities of intervention.
We attempted to address the above limitations by con-
ducting a longitudinal voxel-based morphometry (VBM)
study in treatment-naive adult OCD patients randomized to
participate in either a clinical trial with fluoxetine or group
CBT. Our aims were threefold: first, to document the profile
of brain structural abnormalities associated with OCD
without the confounding factor of previous treatment, we
compared brain morphometric patterns between treatment-
naive OCD patients and healthy controls; second, OCD
patients were compared with controls again after treatment
(either with fluoxetine or CBT) to examine whether brain
volumes would change over the course of treatment; and
third, we performed within-group comparisons (separately
for fluoxetine- and CBT-treated subgroups) to disentangle
possible independent effects of pharmacological and cogni-
tive-behavioral treatment on regional brain morphology.
We focused our investigation within the principal brain
regions previously implicated in imaging studies of OCD
(OFC, ACC, striatum, thalamus, and temporolimbic struc-
tures) (Saxena and Rauch, 2000). A priori, we hypothesized
that: (1) OCD patients would show significant gray matter
(GM) volumetric abnormalities in those brain regions
relative to controls; (2) after successful treatment, brain
volume abnormalities would be attenuated, resulting in
fewer significant differences relative to controls; (3) specifi-
cally, given the supposed effect of SRI treatment in
modulating the activity of frontal-subcortical and limbic
circuits (Bloom and Kupfer, 1995), patients in the fluoxetine
group would exhibit more widespread brain effects after
treatment; and (4) patients undergoing CBT would present
GM volume changes mainly in regions of the medial
prefrontal cortex (medial OFC and rostral/subgenual ACC),
reflecting the primacy of cortico-subcortical top-down
effects associated with extinction processes (Milad et al,
2005, 2007; Phelps et al, 2004).
MATERIALS AND METHODS
Subjects
This investigation is an arm of a research protocol that
involved administering several neurobiological measures
to treatment-naive OCD patients who participated in a larger
clinical trial intended to investigate the effectiveness of
fluoxetine and group CBT in a setting more similar
to clinical practice (clinical registration information: http://
clinicaltrials.govFNCT00680602) (Belotto-Silva et al, 2011).
This project was conducted in our outpatient OCD clinics at
the University of Sa˜o Paulo Medical School, Brazil (protocol,
training, and reliability of instruments can be found
elsewhere) (Hoexter et al, 2009; Miguel et al, 2008).
In brief, patients were referred from primary psychiatric
services or were recruited through the local media (radio/
television/newspapers/internet). Screening procedures
included a telephone assessment, conducted by a trained
psychologist. Once the subject met the initial requirements,
a medical appointment was scheduled in which clinical and
psychiatric assessments, structured clinical diagnostic inter-
views (SCID-I) (First et al, 1997), routine blood tests, and an
electrocardiogram were obtained. Inclusion criteria
comprised: (1) age between 18 and 65 years; (2) primary
DSM-IV diagnosis of OCD; and (3) Yale–Brown Obsessive-
Compulsive Scale (Y-BOCS) scoreX16 or at least 10 if only
obsessions or compulsions were present (only one patient
had total Y-BOCS score o16, scoring 2 for obsessions and
13 for compulsions). Patients were excluded if they had:
(1) previous exposure to any sort of psychotropic medica-
tion (benzodiazepines, antipsychotics, antidepressants,
stimulants, mood stabilizers); (2) previous exposure to at
least 12 sessions of CBT (only 2 patients had been exposed
to CBT before); (3) history of head injury with loss of
consciousness; (4) past/current substance abuse or depen-
dence; (5) lifetime history of psychosis; (6) suicide risk;
(7) any organic disorders that could affect the central
nervous system; (8) contraindications for MRI scanning;
and (9) being pregnant.
Controls were selected among college students and
hospital and university staff, or were recruited through
word of mouth. They were selected according to the same
criteria described above (except for the presence of OCD)
and had no current history of neurological or psychiatric
disorders on the basis of SCID interviews. All participants
provided written informed consent, which had been
approved by the local Institutional Review Board.
From 623 patients referred to our OCD clinic from 2006
to 2008 (Hoexter et al, 2009), 254 were excluded in the
telephone screening and 328 were excluded in the psy-
chiatric medical assessment mainly for not being treatment
naive (Supplementary Figure S1). In all, 41 OCD patients
participated. Similarly, 54 potential healthy controls were
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screened, from which 38 who fulfilled all the criteria for
study entry were selected. It is noteworthy that three
patients and two controls were excluded (Figure 1). There-
fore, 38 treatment-naive OCD patients and 36 controls
who matched for age, gender, socioeconomic status, level of
education, and handedness were studied (Table 1).
Clinical Assessments
The Y-BOCS (Goodman et al, 1989), Dimensional
Yale–Brown Obsessive-Compulsive Scale (DY-BOCS)
(Rosario-Campos et al, 2006), Beck Depression Inventory
(BDI) (Beck et al, 1961), Beck Anxiety Inventory (BAI)
(Beck et al, 1988), and Clinical Global Impression scale
(CGI) (Guy, 1976) were administered before and after
12 weeks of treatment (Hoexter et al, 2009) by interviewers
who were blind to the type of treatment.
On the basis of the SCID, 13 OCD patients met DSM-IV
criteria for current major depression and 10 additional
patients had a history of major depression and/or dys-
thymia. Other SCID-I DSM-IV lifetime diagnoses included
agoraphobia (n¼ 2), panic disorder with agoraphobia
(n¼ 1), panic disorder without agoraphobia (n¼ 3), specific
phobia (n¼ 13), social phobia (n¼ 21), post-traumatic stress
disorder (n¼ 8), generalized anxiety disorder (n¼ 17),
bipolar I (n¼ 1), bipolar II disorder (n¼ 2), somatization
(n¼ 2), hypochondriasis (n¼ 1), body dysmorphic disorder
(n¼ 5), anorexia nervosa (n¼ 3), bulimia nervosa (n¼ 2),
binge-eating disorder (n¼ 2), skin picking (n¼ 8), tricho-
tillomania (n¼ 2), intermittent explosive disorder (n¼ 7),
attention-deficit/hyperactivity disorder (n¼ 3), chronic tics
(n¼ 4), and Tourette’s syndrome (n¼ 2).
Allocation
A specific mode of randomization was used in this study
(Fossaluza et al, 2009). In brief, a computer program was
developed to sequentially allocate patients to each treatment
Figure 1 Study flowchart showing the numbers of participants through each stage of the study.
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group, in which prognostic factors such as gender, age, and
initial Y-BOCS score were inserted in the model. The aim of
this method was to minimize differences between groups by
balancing possible confounders. Consequently, patients
allocated to either group (fluoxetine¼ 19 and CBT¼ 19)
were less likely to differ significantly in terms of major
Table 1 Clinical and Demographic Characteristics of OCD Patients and Controls
Variable OCD (n¼38) Controls (n¼36) Analysis
Mean (SD) U Z p-value
Age, years 31.5 (10.2) 27.8 (7.8) 545.5 1.50 0.13
Age of onset, yearsa 13.1 (7.6) NA F F F
Illness duration, yearsa 18.2 (10.4) NA F F F
Y-BOCS scores
Obsessions 12.2 (3.2) NA F F F
Compulsions 12.9 (2.5) NA F F F
Total 25.1 (5.2) NA F F F
DY-BOCS scoresb
Aggressionc 5.6 (4.6) 0 (0) 216.0 5.94 o0.001
Sexual/religiousd 3.4 (4.8) 0 (0) 432.0 3.99 o0.001
Symmetrye 7.6 (3.8) 0.2 (0.5) 85.0 6.83 o0.001
Contaminationf 5.5 (5.1) 0 (0) 270.0 5.46 o0.001
Hoardingg 3.2 (3.5) 0.1 (0.4) 323.0 4.76 o0.001
BDI 17.3 (9.4) 2.6 (2.7) 75 6.61 o0.001
BAI 17.1 (11.7) 1.9 (1.6) 64.5 6.72 o0.001
N (%) w2 df p-value
Gender, female 23 (60.5) 23 (63.9) 0.09 1 0.77
Caucasian 34 (89.5) 28 (77.8) 1.10 1 0.29
Socioeconomic status
Classes a/b (higher) 23 (60.5) 25 (69.4) 0.64 1 0.42
Classes c/d/e (lower) 15 (39.5) 11 (30.6)
Level of educationh
Higher 14 (36.8) 13 (36) 0.32 2 0.85
Middle 22 (57.9) 22 (61.1)
Lower 2 (5.3) 1 (2.8)
Right-handed 37 (97.4) 36 (100) 0.96 1 0.33
Presence of a symptom dimension (DY-BOCS)
Aggressionc 29 (76.3) 1 (2.8) 41.473 1 o0.001
Sexual/religiousd 16 (42.1) 0 (0) 19.339 1 o0.001
Symmetrye 34 (89.5) 7 (19.4) 36.693 1 o0.001
Contaminationf 24 (63.2) 2 (5.6) 26.914 1 o0.001
Hoardingg 21 (55.3) 3 (8.3) 18.580 1 o0.001
Abbreviations: BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; df, degree of freedom; DY-BOCS, Dimensional Yale–Brown Obsessive-Compulsive
Scale; NA, not applicable; OCD, obsessive-compulsive disorder; U, Mann–Whitney U-test; Y-BOCS, Yale–Brown Obsessive-Compulsive Scale.
aOne data value is missing.
bScores vary from 0 to 15 for each dimension.
cObsessions about harm due to aggression/injury/violence/natural disasters, and related compulsions.
dObsessions concerning sexual/moral/religious obsessions, and related compulsions.
eObsessions about symmetry/‘just-right’ perceptions, and compulsions to count or order/arrange.
fContamination obsessions and cleaning compulsions.
gObsessions and compulsions related to hoarding.
hHigher: complete tertiary education; middle: incomplete tertiary and complete secondary education; incomplete secondary education.
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clinical and demographical characteristics (Supplementary
Table S1).
Fluoxetine Treatment
Patients received fluoxetine (up to 80 mg/day) for 12 weeks,
starting at 20 mg/day in the first week, with weekly increases
of 20 mg/day (Diniz et al, 2010). Medical appointments were
scheduled every 4 weeks to monitor side effects and
treatment compliance. Of the 14 patients who completed
the treatment (74% of the initial sample), all reached the
maximal dose of 80 mg/day without reporting major side
effects, except for one subject who could not tolerate doses
higher than 20 mg/day because of gastrointestinal effects
and tremor. In all, 13 post-fluoxetine MRI scans were
analyzed. Reasons for not analyzing a second MRI scan
and reasons for dropouts are presented in Figure 1. Non-
completers were not statistically different from completers
in terms of age, age at onset of symptoms, illness duration,
Y-BOCS, DY-BOCS, BDI, and BAI scores.
Group CBT Treatment
Patients were divided into subgroups of 6–8 people each
and attended a weekly 2-h standardized CBT session for
12 weeks. The groups were coordinated by a psychologist
with several years of experience in behavior therapy, who
was trained by the author of the group CBT protocol
(Cordioli et al, 2002; Volpato Cordioli et al, 2003). Patients
who missed more than two consecutive sessions were
considered dropouts. The protocol consisted of (Volpato
Cordioli et al, 2003): session 1Fpsychoeducational infor-
mation; session 2Fdevelopment of symptoms hierarchies;
session 3Fintroduction to exposure with response pre-
ventionFE/RP; sessions 4–7FE/RP exercises and cogni-
tive techniques; session 8Ffamily session, and sessions
9–12Freview of E/RP and cognitive techniques. In all, 15
patients (79% of the initial sample) completed the group
CBT treatment, and 13 post-CBT MRI scans were analyzed.
Reasons for not analyzing a second MRI scan and reasons
for dropouts are presented in Figure 1. The non-completers
were not statistically different from completers in terms of
age, age at onset of symptoms, illness duration, Y-BOCS,
DY-BOCS, BDI, and BAI scores.
Image Acquisition and Processing
Patients were scanned at baseline and after 12 weeks of
treatment. Healthy controls were scanned just once at
baseline, given that there is evidence that such a small
period of time does not significantly affect GM measures in
healthy subjects as assessed with VBM (Ho¨lzel et al, 2011;
Lyoo et al, 2010; Lazaro et al, 2009). Images were acquired
using a 1.5-T GE Signa scanner (General Electric, Milwau-
kee, WI, USA). Contiguous 1.6-mm axial images across the
entire brain were obtained (T1-3D SPGR sequence,
TE¼ 4.20 ms, TR¼ 10.5 ms, flip angle¼ 15, acquisition
matrix¼ 256 192) and interpolated using ZIP2 to a final
voxel size of 0.94 0.94 0.80 mm3 (248 slices). VBM
processing was executed using the Statistical Parametric
Mapping (SPM5) package (Wellcome Department of
Imaging Neuroscience, London, UK), performed in Matlab
(Mathworks, Sherborn, MA), using the default parameters
implemented in the VBM5 Toolbox (http://dbm.neuro.
uni-jena.de/vbm/). This protocol uses the unified segmenta-
tion approach (Ashburner and Friston, 2005), which
integrates the processes of tissue classification, MRI
inhomogeneity bias correction, and spatial normalization
to the standard SPM T1-MRI template, based on 152 healthy
subjects from the Montreal Neurological Institute (MNI)
(Mazziotta et al, 1995), using linear (12-parameter affine)
and non-linear transformations. The extension of Hidden
Markov Random Field approach available in the VBM5 tool
box was used, aimed at increasing the quality of image
segmentation (Cuadra et al, 2005). Subsequently, the final
tissue maps of GM, white matter, and brain-spinal fluid
were modulated by the Jacobian determinants derived from
spatial normalization to the MNI standard space. This
enabled brain structures that had their volumes reduced
after spatial normalization to have their total counts
restored by an amount proportional to the degree of
volume shrinkage and thus allowed testing for regional
differences in the absolute volume amount of GM (Good
et al, 2001). Voxel sizes of segmented and spatially normal-
ized images equaled 1 1 1 mm3. Finally, images from
OCD patients and controls were smoothed using a 12-mm
Gaussian kernel.
Statistical Analysis
Comparisons of GM volume were performed between and
within groups with VBM using the general linear model
(Friston et al, 1994). Only voxels with values above an
absolute threshold of p¼ 0.05 for differentiating GM from
other tissues entered the analyses. A measure of the total
amount of GM was entered as confound in an analysis
of covariance. In each comparison, two t-statistic maps,
corresponding to opposite contrasts (volume decrease and
increase), were generated and displayed into standard space
at a threshold of po0.001, uncorrected. Each statistical map
was then inspected for the presence of clusters of significant
differences in regions where volumetric abnormalities had
been predicted a priori (orbitofrontal, anterior cingulate
and temporolimbic cortices, thalamus, and caudate–puta-
men) using the small volume correction (SVC) method
included in SPM toolbox, with the purpose of constraining
the total number of voxels included in the analyses. Each
region was circumscribed by merging the spatially normal-
ized region-of-interest (ROI) masks that are available within
the Anatomical Automatic Labeling SPM toolbox. Anatom-
ical masks were used separately in each hemisphere (left
and right, respectively), resulting in search volumes of 7704
and 7976 voxels for the superior lateral OFC; 7104 and 8120
voxels for the middle lateral OFC; 13 520 and 13 631 voxels
for the inferior lateral OFC; 5752 and 6848 voxels for the
medial OFC; 7696 and 7952 voxels for the caudate nucleus;
8039 and 8438 voxels for the putamen; 8435 and 8174 voxels
for the thalamus; 11 200 and 10 504 voxels for the anterior
cingulate gyrus; 1760 and 1984 voxels for the amygdala;
7456 and 7568 voxels for the hippocampus; and 7824 and
9056 voxels for the parahippocampal gyrus. Findings of
these hypothesis-driven, SVC-based analyses were reported
as significant if surviving family-wise error (FWE) correc-
tion for multiple comparisons (po0.05) over the respective
GM changes in OCD patients
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ROI, with voxel clusters comprising at least 20 voxels.
For unpredicted findings in other GM regions, we used
the FWE-corrected po0.05 level over the whole brain.
In all analyses, we converted MNI coordinates of voxels of
maximal statistical significance to the Talairach and
Tournoux (1988) system (Brett et al, 2002).
RESULTS
Treatment Outcome
After treatment, OCD patients as a whole exhibited a
significant decrease in the severity of obsessive-compulsive
symptoms (mean±SD pre- vs post-treatment Y-BOCS:
24.9±5.2 vs 16.3±8.1; decrements of 34.5%; p¼ 0.001)
and depressive symptoms (pre- vs post-treatment BDI:
14.9±8.0 vs 9.8±7.6; decrements of 34.2%; p¼ 0.007).
Within-group comparisons (fluoxetine-treated¼ 13 and
CBT-treated¼ 13) revealed significant OCD severity reduc-
tions for both treatments subgroups (pre- vs post-treatment
Y-BOCS: 23.4±5.0 vs 14.8±6.3; decrements of 36.7%;
p¼ 0.005 for fluoxetine and 26.5±5.1 vs 17.7±9.6; decre-
ments of 33%; p¼ 0.003 for CBT), with no statistical
difference between treatments. In all, 5 out of 13 fluoxetine-
treated patients (38.4%) and 6 out of 13 CBT-treated
patients (46.1%) were considered full responders (defined
as a minimum reduction of 35% on the Y-BOCS and a
‘much-improved’ or ‘very-much-improved’ CGI-improve-
ment scores for OCD).
Subjects also experienced a decrease in depressive
symptoms in both treatment subgroups, but this difference
was only statistically significant for CBT (pre- vs post-
treatment BDI: 14.7±9.2 vs 9.1±9.0; decrements of 38.1%;
p¼ 0.018 for CBT and 15.0±7.1 vs 10.5±6.4; decrements of
30%; p¼ 0.1 for fluoxetine).
MRI Comparisons: Treatment-Naive OCD Patients at
Baseline vs Controls
The total GM volume measured in milliliters in the seg-
mented images was 915.12±61.34 in the OCD group and
932.51±39.26 in healthy control subjects (t¼1.443,
df¼ 72, p¼ 0.153).
VBM analyses indicated that there was a significantly
smaller GM volume in the left putamen (dorsal rostral
portions) in OCD patients than in controls (Table 2 and
Figure 2a). A similar pattern of between-group differences
involving the putamen was seen after exclusion of patients
who met criteria for current major depression (n¼ 13)
(Table 2). In addition, this subgroup of non-depressed OCD
patients also presented clusters of significant smaller GM
volume in the left (Table 2, Figure 2b) and right medial OFC
(Table 2, Figure 2c) and right ACC (Table 2, Figure 2c).
No clusters of significant greater GM volumes were found
within the principal brain areas predicted a priori in the
OCD sample. There were also no clusters of regional
changes of greater or smaller GM volumes in other
unpredicted brain regions considering a p-value o0.05,
corrected for multiple comparisons over the whole brain.
For exploratory purposes, given that other regions appear to
be involved in OCD, such as the dorsolateral prefrontal,
posterior cingulate, and parietal cortices (Menzies et al,
2008; Busatto et al, 2000), data of unpredicted GM volumes
using a less stringent threshold of po0.001 for the whole
brain (uncorrected for multiple comparisons) are listed
in Supplementary Table S2.
In the OCD group, there were no significant linear
correlations between GM volumes involving the regions
shown to be altered in the between-group comparisons
and either of the variables: age at onset of symptoms, illness
duration, Y-BOCS, DY-BOCS, BDI, and BAI scores. The
threshold for considering a correlation as statistically signi-
ficant was set at a p-valueo0.001, uncorrected for multiple
comparisons over the entire brain, after covarying out the
effect of the total amount of GM.
We also performed an analysis comparing pre-treatment
GM volumes specifically in the OCD subgroup who subse-
quently completed either the fluoxetine or CBT treat-
ment protocols (n¼ 26) against the control group (n¼ 36).
This analysis confirmed the findings of significant smaller
GM volume in the left putamen in OCD patients relative
to controls (219 voxels; peak coordinates¼27, 13, 2;
Table 2 Differences in Regional Gray Matter Volumes between Patients with OCD and Controls
Brain region (SVC)a Direction of difference Coordinates (x, y, z)b BAc Peak Z-scored Number of voxelse p (FWE)f
Overall OCD group (n¼ 38) vs controls (n¼ 36)
Left putamen Decreased in OCD 28, 12, 3 F 4.28 819 0.001
OCD subjects without major depression (n¼ 25) vs controls
Left putamen Decreased in OCD 27, 14, 2 F 4.01 695 0.004
Left medial orbitofrontal cortex Decreased in OCD 13, 50, 9 10 3.32 59 0.025
Right medial orbitofrontal cortex Decreased in OCD 14, 41, 2 10 3.64 49 0.011
Right anterior cingulate cortex Decreased in OCD 14, 41, 2 32 4.08 418 0.004
aEach region was circumscribed using the small volume correction (SVC) approach, with anatomically defined volume-of-interest masks.
bTalairach and Tornoux (1988) coordinate of the voxel of maximal statistical significance within each region.
cApproximate Brodmann’s areas.
dZ-score for the voxels of peak statistical significance within each volume of interest.
eTotal number of contiguous voxels in each region that surpassed the initial cutoff of Z43.09.
fFamily-wise error (FWE) correction for multiple comparisons at the level of individual voxels within the respective volume of interest.
GM changes in OCD patients
MQ Hoexter et al
739
Neuropsychopharmacology
Z¼ 3.59; peak voxel p-FWE¼ 0.016) (1350 voxels; peak
coordinates¼27, 13, 2; Z¼ 3.77; peak voxel p-FWE¼
0.009). No GM alterations involving regions within the
medial orbitofrontal and anterior cingulate cortices were
observed.
MRI Comparisons: Treated OCD Patients vs Controls
The analyses comparing post-treatment GM volumes in
OCD patients who completed the treatment protocols
(n¼ 26) against the control group indicated that there were
no longer significant findings of smaller GM volume in the
left putamen in OCD subjects relative to controls, as it had
been found in the pre-treatment comparisons between OCD
patients and controls. There were no other clusters of
significant GM volume differences between treated OCD
patients and controls, either in the other areas where
volume abnormalities had been hypothesized a priori or in
unpredicted brain regions.
Pre- vs Post-Treatment MRI Comparisons within the
OCD Group
To test our hypothesis that fluoxetine and CBT exert
different modulations over the volume of brain regions
relevant to the pathophysiology of OCD, we conducted
voxelwise within-group analysis comparing GM volumes
pre vs post treatment in the two OCD subgroups (pre vs
post fluoxetine¼ 13, pre vs post CBT¼ 13). None of these
analyses revealed significant changes in GM volumes after
treatment, either with a threshold of po0.001 or a less
stringent threshold of po0.01, uncorrected for multiple
comparisons, nor in other, unpredicted brain regions.
Finally, for exploratory purposes, we extracted mean GM
volume values from the spatially normalized images of each
patient before and after treatment, using bilateral ROI
masks placed on the putamen, medial OFC, and ACC. These
within-group ROI comparisons showed, in fluoxetine-
treated OCD patients (n¼ 13), a significant increase in
GM volume in the left putamen (p¼ 0.012) after treatment.
Conversely, there were no statistically significant GM
volume changes after treatment in any of the ROIs in
OCD patients who underwent the CBT program (n¼ 13)
(Table 3). It is noteworthy that these results were not
influenced by differences in the percentage of changes in
comorbid depressive symptoms.
DISCUSSION
This study investigated post-treatment morphometric brain
alterations in adult treatment-naive OCD patients partici-
pating in a randomized clinical trial comparing pharma-
cotherapy and psychotherapy. A methodological advantage
of enrolling treatment-naive patients in such a study
design is the exclusion of potentially confounding
effects of previous treatments on GM brain volumes. The
VBM analysis revealed, in treatment-naive OCD patients,
decreased GM volume in the left putamen compared with
controls. In a subgroup of OCD patients without comorbid
depression, reduced GM volumes in the bilateral medial
orbitofrontal and left anterior cingulate cortices were also
observed, reinforcing the involvement of these structures in
the pathophysiology of OCD. After successful treatment
with either SRIs or CBT, GM volume abnormalities in the
left putamen presented in the whole sample of OCD patients
were no longer detectable relative to controls. ROI-based
within-group comparisons revealed that GM volume in the
left putamen significantly increased in fluoxetine-treated
patients, whereas no significant GM volume changes were
observed in CBT-treated patients.
Fluoxetine and Group CBT Treatment Outcomes
Weekly group CBT has been shown to be as effective as
fluoxetine treatment in reducing obsessive-compulsive
symptoms. This study adds to evidence from earlier papers
that weekly group CBT is as effective as selective SRIs in
treating OCD (Sousa et al, 2006). It is important to highlight
that the group approach lowers costs considerably, hence
making CBT accessible to a larger numbers of patients.
Figure 2 Brain regions where there were foci of significantly gray matter volume differences in obsessive-compulsive disorder (OCD) patients relative to
healthy control subjects. (a) Lesser regional gray matter volume in OCD patients (n¼ 38) vs healthy controls (n¼ 36) in the left putamen. (b) Lesser regional
gray matter volume in OCD patients without major depression (n¼ 25) vs healthy controls (n¼ 36) in the left medial orbitofrontal cortex. (c) Lesser
regional gray matter volume in OCD patients without major depression (n¼ 25) vs healthy controls (n¼ 36) encompassing the right anterior cingulate and
medial orbitofrontal cortices.
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Baseline Brain Volume Abnormalities in
Treatment-Naive OCD Patients vs Controls
Neuroimaging studies have implicated a dysfunction of
frontostriatal regions in the pathophysiology of OCD (Insel,
1992; Rauch, 2000; Saxena et al, 2000). Although the
direction of regional GM volumetric abnormalities reported
in the literature has not always been consistent across
morphometric MRI studies, our results converge with the
findings from two recent VBM meta-analysis that demon-
strated GM alterations in OCD patients encompassing
territories within the striatum, orbitofrontal, and anterior
cingulate cortices (Radua et al, 2009; Rotge et al, 2010). It is
noteworthy that although our results showed putaminal
decrements in OCD, Radua and Mataix-Cols (2009) and
Rotge et al (2010) demonstrated increased GM within this
region. Another recent VBM meta-analysis demonstrated
that OCD was associated with greater putaminal volume,
whereas the opposite was observed in other anxiety
disorders (such as posttraumatic stress disorder and panic
disorder) (Radua et al, 2010). Inconsistencies in the
direction of these abnormalities may be partially interpreted
as a consequence of methodological differences across
separate MRI studies, such as small and heterogeneous
samples of OCD participants, matching criteria, voxelwise
statistical testing, and image processing details (Ferreira
and Busatto, 2010; Menzies et al, 2008). In this study,
aiming to investigate a real-world OCD population, we did
not exclude many comorbidities including several anxiety
disorders, which may have added variability to our findings.
Moreover, an alternative explanation for such a disparity is
the fact that we investigated treatment-naive adult OCD
patients. This may be an important difference, given that
the majority of studies included in these meta-analyses
investigated OCD patients who were currently taking or had
already taken medication. The few studies that investigated
treatment-naive patients were performed in children with a
short illness duration. Therefore, our results may suggest
that previous exposure to medication, regardless of whether
OCD patients were medicated or non-medicated at the time
of MRI scanning, may also have an important role in the
variability of results. It is equally important to highlight,
given that OCD and major depressive disorder are mediated
by distinct but partially overlapping neural systems
(Cardoner et al, 2007; Saxena et al, 2001), that our baseline
findings of altered GM volumes were present in the OCD
sample independently of the presence of current major
depression.
In particular, the dorsal subregion of the rostral putamen
implicated in this study receives projections from the
dorsolateral prefrontal cortex (critical to higher cognitive
processes), as well as premotor and motor areas (involved
in motor planning and execution) (Haber, 2003). Thus,
alterations in this striatal subregion could be related to
cognitive and motor impairments that are highly frequently
reported in OCD patients (Chamberlain et al, 2005; Menzies
et al, 2008), such as mental inflexibility and impaired motor
inhibition.
Our finding of smaller GM volume in the medial OFC and
ACC is consistent with previous results reported in imaging
studies of OCD (Pujol et al, 2004; Rauch et al, 1994; Valente
et al, 2005, Radua et al, 2009; Rotge et al, 2010). Given their
connections with the ventral striatum, amygdala and insula,
the medial OFC, and ACC are important regulatory nodes
monitoring motivation and emotional responses (Cardinal
et al, 2002; Phillips et al, 2003). Recently, functional imaging
studies have provided evidence that cortical connectivity
of different subregions within the striatum, involving
both cognitive and emotional processing, is disrupted
in OCD (Harrison et al, 2009). Therefore, our findings of
GM abnormalities in specific subregions of the striatum
(putamen), OFC, and ACC provide structural substrate
for functional connectivity alterations observed in OCD.
The exact neurobiological mechanisms underlying how
morphometric changes of specific brain regions may
influence actual physiological activity of the putative
cortico-striatal loops are not fully understood. It may be
speculated that alterations in GM volumes could be due to
changes in the number of neurons, glial cells, or synaptic
arborization that could ultimately inhibit or facilitate
Table 3 Region-of-Interest Analysis of Gray Matter Volume Differences in OCD Patients Before and After Treatment
Group Brain region Pretreatment, mean (SD), cm3 Post-treatment, mean (SD), cm3 Difference (%) Z-score p-valuea
Fluoxetine Left putamen 3.63 3.82 5 2.50 0.012
Right putamen 4.05 4.18 3.1 1.62 0.1
Left mOFC 3.43 3.41 0.6 1 0.32
Right mOFC 4.26 4.27 0.2 0.27 0.78
Left ACC 7.01 6.97 0.6 0.62 0.53
Right ACC 5.86 6.06 3.3 1.15 0.25
CBT Left putamen 3.91 3.9 0.2 0.56 0.57
Right putamen 4.38 4.32 1.4 0.85 0.39
Left mOFC 3.41 3.4 0.3 0.27 0.78
Right mOFC 4.26 4.26 0 0.000 1
Left ACC 7.08 7.12 0.6 0.51 0.61
Right ACC 5.87 6.04 2.8 1.26 0.21
Abbreviations: ACC, anterior cingulate cortex; mOFC, medial orbitofrontal cortex; OCD, obsessive-compulsive disorder.
aWilcoxon’s test for paired comparisons.
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cortico-striatal communication. It is remarkable that
surgical treatments for treatment-refractory OCD, such as
stereotactic ablation and deep brain stimulation that intent
to modulate specific cortico-striatal circuits (Greenberg
et al, 2010), target regions closely located to our putaminal
finding.
MRI Findings in OCD Patients after Treatment with
Fluoxetine or CBT
The results of our post-treatment comparison between
OCD patients and healthy controls suggest that GM volume
abnormalities in the left putamen were attenuated after
treatment. These findings may indicate that OCD treatment,
regardless of the modality used modulates GM volumes
in OCD patients. If it is the case, this interpretation is
consistent with several functional imaging studies that
have reported metabolic normalization after either phar-
macotherapy or behavior therapy for OCD (Baxter et al,
1992; Perani et al, 1995; Saxena et al, 2002; Swedo et al,
1992).
However, the above interpretation has to be made
cautiously, as there are other plausible explanations for
these results. Loss of significant GM differences between
post-treated patients and controls does not necessarily
prove major changes in regional GM volume in OCD
subjects, but may reflect minor effects or even increased
experimental noise at follow-up.
One second alternative interpretation is that modulation
of brain volume abnormalities would be the result of only
one of the two specific treatments, either SRI or CBT, rather
than reflecting overall effects of clinical improvement per se.
Indeed, although the voxelwise within-group comparisons
of pre- vs post-treatment MRI data did not show significant
volumetric brain changes after treatment in OCD patients,
our exploratory ROI analysis demonstrated a significant
left putaminal volume increase after fluoxetine treatment,
whereas no volume changes after CBT were observed in any
of the brain regions investigated. Interestingly, a longi-
tudinal VBM study reported volume increments in the
striatum of OCD children after exposure to selective SRIs
(Lazaro et al, 2009). It is noteworthy that this finding was
obtained only when a less stringent threshold was used. It is
possible that GM modifications after treatment were not
detectable by VBM because of a limitation of this approach
in investigating subtle changes spread throughout large
portions of specific GM nuclei (Szeszko et al, 2008). In this
sense, ROI approaches may be more suitable for detecting
subtle GM changes that take place over an entire anatomical
brain structure, in contrast to VBM, which requires a more
robust GM volume change localized in particular discrete
areas. It has been suggested in previous longitudinal
morphometric neuroimaging investigations that neuro-
biological changes after treatment may be specific to SRIs
rather than to CBT (Benazon et al, 2003; Gilbert et al, 2000;
Lazaro et al, 2009; Rosenberg et al, 2000; Szeszko et al,
2004). In this regard, given that the majority of longitudinal
volumetric studies were performed in children with short
illness duration, our findings complement previous data by
demonstrating similar results in chronic adult patients. We
speculate that different neural pathways and neurotrans-
mitters are associated with each type of intervention. It has
been demonstrated that modulations in serotonergic neuro-
transmission by SRIs mediate neuroplasticity (neurogenesis
and gliogenesis) in various cortical and subcortical
structures involved in OCD (Czeh et al, 2007; Kodama
et al, 2004; Soumier et al, 2009). On the other hand, given
the role of the medial prefrontal cortex in the modulation of
extinction memory of conditioned fear response (Milad
et al, 2005, 2007; Phelps et al, 2004), it is postulated that the
brain sites of action of CBT primarily encompass regions
within the medial OFC and rostral/subgenual ACC. In
recent years, there has been increasing interest in the
glutamatergic system in OCD (MacMaster et al, 2008) and
its role in extinction learning (Davis and Myers, 2002).
Previous studies have shown that glutamatergic manipula-
tion within the medial prefrontal cortex enhances synaptic
plasticity and facilitates consolidation of extinction
(Burgos-Robles et al, 2007).
Finally, although we did document medial OFC and ACC
volume abnormalities in OCD patients, there were no GM
volume changes after treatment in any regions of the frontal
cortex in either the fluoxetine or CBT OCD subgroups.
Speculatively, given that SRIs are considered to modulate
serotonin transmission earlier in subcortical regions and
later in cortical ones (Blier and Bouchard, 1994; el Mansari
et al, 1995) and that treatment effects with SRIs and CBT
can be delayed beyond 12 weeks (Greist et al, 1995),
volumetric changes in frontal cortical territories may
require longer periods to take place. Moreover, given the
impossibility of patients to choose the type of treatment, the
lack of a within-group CBT effect on MRI volumes could
have been due to variability in the engagement to perform
that intervention.
Methodological Considerations and Conclusions
The results reported herein must be interpreted with
caution because of several limitations. First, the small
sample size, mainly in the follow-up arm of the study, may
have limited our power to detect differences in other brain
regions. Second, the CBT approach was applied in a group
setting, which may be different than providing one-to-one
treatment. Third, given that we adopted broad inclusion
criteria to build a setting closer to clinical practice, our OCD
patients presented many comorbidities which may have
added variability to our findings. Fourth, our randomized
clinical trial did not include a placebo-treated group. Fifth,
we did not perform a second MRI scan in controls. Sixth,
GM volume within-group differences were only observed in
the ROI analyses, whereas no within-group differences were
detected in the VBM approach. This limits the robustness of
the post hoc tests. Therefore, our findings that fluoxetine
and CBT may have different treatment effects on the brain
should be interpreted as exploratory and deserve replication
before generalization.
In conclusion, our results of smaller GM volume in
the putamen, medial OFC, and ACC of treatment-naive
OCD patients highlight the involvement of orbitofrontal/
cingulo-striatal loops in the pathophysiology of OCD. ROI
exploratory analyses suggest that fluoxetine and CBT may
have distinct neurobiological mechanisms of action. Further
MRI studies are warranted using placebo-controlled designs
in larger samples of OCD patients, with longer follow-up
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periods to allow investigation as to whether GM changes
reported herein may be replicated and extended to other
brain regions after different treatment interventions.
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